XML 42 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Selected Quarterly Financial and Supplementary Data
12 Months Ended
Dec. 31, 2017
Notes to Financial Statements  
Quarterly Financial Information [Text Block]
CAMBREX CORPORATION AND SUBSIDIARIES
 
SELECTED QUARTERLY FINANCIAL
AND SUPPLEMENTARY
DATA
- UNAUDITED
(in thousands, except per share data)
 
   
1st
   
2nd
   
3rd
   
4th
 
   
Quarter
   
Quarter
   
Quarter
   
Quarter
 
2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gross sales
  $
103,711
    $
134,487
    $
112,233
    $
175,505
 
Net revenues
   
105,006
     
134,554
     
112,619
     
182,277
 
Gross profit
   
46,825
     
57,502
     
46,889
     
78,871
 
Income from continuing operations (1)
   
21,115
     
25,124
     
17,276
     
40,249
 
(Loss)/income from discontinued operations (3)
   
(1,250
)    
(94
)    
20
     
10
 
Net income
   
19,865
     
25,030
     
17,296
     
40,259
 
                                 
Earnings per share of common stock: (4)
                               
Basic
   
0.61
     
0.77
     
0.53
     
1.23
 
Diluted
   
0.60
     
0.75
     
0.52
     
1.20
 
Average shares:
                               
Basic
   
32,454
     
32,629
     
32,749
     
32,810
 
Diluted
   
33,365
     
33,469
     
33,512
     
33,532
 
 
   
1st
   
2nd
   
3rd
   
4th
 
   
Quarter
   
Quarter
   
Quarter
   
Quarter
 
2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gross sales
  $
93,935
    $
119,054
    $
99,867
    $
178,682
 
Net revenues
   
94,741
     
118,638
     
99,399
     
177,866
 
Gross profit
   
38,899
     
48,557
     
37,602
     
79,167
 
Income from continuing operations (2)
   
14,845
     
20,810
     
13,721
     
37,949
 
Loss from discontinued operations (3)
   
(263
)    
(316
)    
(4,503
)    
(565
)
Net income
   
14,582
     
20,494
     
9,218
     
37,384
 
                                 
Earnings per share of common stock: (4)
                               
Basic
   
0.46
     
0.64
     
0.29
     
1.16
 
Diluted
   
0.44
     
0.62
     
0.28
     
1.13
 
Average shares:
                               
Basic
   
31,886
     
32,063
     
32,149
     
32,240
 
Diluted
   
32,771
     
32,926
     
32,999
     
33,107
 
 
(
1
)
Income from continuing operations for the first, second, third, and
fourth
quarters includes a favorable impact to tax expense of
$2,654
,
$1,725,
$735,
and
$122,
respectively, from the adoption of ASU
2016
-
09,
and expense of
$117
in the
fourth
quarter as a result of the change in enacted tax rates in the U.S. and the toll tax.
 
(
2
)
Income from continuing operations
for the first, second, third, and
fourth
quarters includes
$290
of expense,
$154
of expense, a
$47
benefit and
$761
of expense, respectively, for restructuring related to the decision to sell our finished dosage form facility in Hyderabad, India.
 
(
3
)
Discontinued operations include
charges and reimbursements for environmental remediation related to sites of divested businesses.
 
(
4
)
Earnings per share calculations for each of the quarters are based on the weighted average number of shares outstanding for each period. As such, the sum of the quarters
may
not
necessarily equal the earnings per share amount for the year.